Skip to content

Adnexus Therapeutics, founded in 2003, was a biopharmaceutical company focused on the development and commercialization of Adnectins as a new class of therapeutics based on human fibronectin and designed to show high potency, specificity, stability, favorable half-life, and high yield E. coli production. Adnexus was acquired in 2007 by Bristol-Myers Squibb Company (NYSE: BMY) for $430M.

Latest News from Adnexus Therapeutics